Why Opiant Pharmaceuticals Shares Are Soaring Today
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy volunteers compared 3 mg nasal nalmefene hydrochloride with 4 mg nasal naloxone hydrochloride in reversing respiratory depression produced by remifentanil, a synthetic opioid. The two study drugs were…
Benzinga ·